CEFAMASTER was trialled in the Waikato region in field trials - on six pasture fed, spring-calving herds. CEFAMASTER had outstanding results in this study.
The study was separated into two trials:
The prophylactic trial included all cows with a Somatic Cell Count of equal or less than 150,000 cells/ml and no history of clinical mastitis. This allowed a proportion of this group to go without dry cow therapy.
intramammary infection trial
somatic cell count trial
The cows were then separated into three groups and milk samples were taken from each quarter post calving to assess quarters with a new intramammary infection and the somatic cell count of each cow. Trials show the infection in untreated cows increased significantly.
clinical mastitis trial
No treatment
cepravin
cefamaster
In the 21 days following calving, the risk of clinical mastitis increased in untreated cows.
Therapeutic Trial
>150,000
All cows with a somatic cell count greater than 150,000 cells/ml and/or a history of clinical mastitis in the previous lactation were allocated into the Therapeutic trial.
somatic cell count 1st herd trial
somatic cell count 6 days post PARTUM
The cows were separated into 2 groups:
results show no difference in the somatic cell counts of cows at the first herd test or in individual quarters up to 6 days after calving.
clinical mastitis trial
cepravin
cefamaster
In the 21 days following calving, the risk of clinical mastitis increased in untreated cows.
dry cow therapy made easy
* TRIAL DATA FROM A RANDOMISED, NON-INFERIORITY TRIAL OF A NEW CEPHALONIUM DRY-COW THERAPY
McDougall S. New Zealand Veterinary Journal, Volume 58, Issue 1, pp 45-48, Feb 2010
proudly available from your local veterinary clinic.
